Discovery of Orally Bioavailable Ligand Efficient Quinazolindiones as Potent and Selective Tankyrases Inhibitors

被引:4
|
作者
Qin, Donghui [1 ]
Lin, Xiaojuan [2 ]
Liu, Zhi [2 ]
Chen, Yan [2 ]
Zhang, Zhiliu [2 ]
Wu, Chengde [2 ]
Liu, Linlin [2 ]
Pan, Yan [2 ]
Laquerre, Sylvie [1 ]
Emery, John [1 ]
Fergusson, Jeff [3 ]
Roland, Kimberly [3 ]
Keenan, Rick [1 ]
Oliff, Allen [1 ]
Kumar, Sanjay [1 ]
Cheung, Mui [1 ]
Su, Dai-Shi [1 ]
机构
[1] GlaxoSmithKline, Alternat Discovery & Dev, Virtual PoC DPU, King Of Prussia, PA 19406 USA
[2] WuXi AppTec, Shanghai 200131, Peoples R China
[3] GlaxoSmithKline, Platform Technol & Sci, IVIVT, King Of Prussia, PA 19406 USA
来源
ACS MEDICINAL CHEMISTRY LETTERS | 2021年 / 12卷 / 06期
关键词
Tankyrases; inhibitors; quinazolindiones; MECHANISMS;
D O I
10.1021/acsmedchemlett.1c00160
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
We report herein the discovery of quinazolindiones as potent and selective tankyrase inhibitors. Elucidation of the structure-activity relationship of the lead compound 1g led to truncated analogues that have good potency in cells, pharmacokinetic (PK) properties, and excellent selectivity. Compound 21 exhibited excellent potencies in cells and proliferation studies, good selectivity, in vitro activities, and an excellent PK profile. Compound 21 also inhibited H292 xenograft tumor growth in nude mice. The synthesis, biological, pharmacokinetic, in vivo efficacy studies, and safety profiles of compounds are presented.
引用
收藏
页码:1005 / 1010
页数:6
相关论文
共 50 条
  • [1] Discovery of chiral dihydropyridopyrimidinones as potent, selective and orally bioavailable inhibitors of AKT
    Parthasarathy, Saravanan
    Henry, Kenneth
    Pei, Huaxing
    Clayton, Josh
    Rempala, Mark
    Johns, Deidre
    De Frutos, Oscar
    Garcia, Pablo
    Mateos, Carlos
    Pleite, Sehila
    Wang, Yong
    Stout, Stephanie
    Condon, Bradley
    Ashok, Sheela
    Lu, Zhohai
    Ehlhardt, William
    Raub, Tom
    Lai, Mei
    Geeganage, Sandaruwan
    Burkholder, Timothy P.
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2018, 28 (10) : 1887 - 1891
  • [2] Discovery of β-benzamido hydroxamic acids as potent, selective, and orally bioavailable TACE inhibitors
    Duan, James J. -W.
    Chen, Lihua
    Lu, Zhonghui
    Xue, Chu-Biao
    Liu, Rui-Qin
    Covington, Maryanne B.
    Qian, Mingxin
    Wasserman, Zelda R.
    Vaddi, Krishna
    Christ, David D.
    Trzaskos, James M.
    Newton, Robert C.
    Decicco, Carl P.
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (01) : 241 - 246
  • [3] Discovery and optimization of potent, selective, and orally bioavailable Jak1 inhibitors
    Zak, Mark
    Johnson, Adam
    Van Abbema, Anne
    Waszkowycz, Bohdan
    Eigenbrot, Charles
    Chang, Christine
    Hurley, Christopher
    Hanan, Emily
    Kenny, Jane
    Kulagowski, Janusz
    DeVoss, Jason
    Murray, Jeremy
    Balazs, Mercedesz
    Steffek, Micah
    Koehler, Michael
    Ghilardi, Nico
    Chakravarty, Paroma
    Lupardus, Patrick
    Gibbons, Paul
    Dragovich, Peter
    Bergeron, Philippe
    Pulk, Rebecca
    Mendonca, Rohan
    Savage, Scott
    Labadie, Sharada
    Gradl, Stefan
    Ward, Stuart
    Blair, Wade
    Jia, Wei
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 243
  • [4] Discovery of Pyridinyl Acetamide Derivatives as Potent, Selective, and Orally Bioavailable Porcupine Inhibitors
    Cheng, Dai
    Liu, Jun
    Han, Dong
    Zhang, Guobao
    Gao, Wenqi
    Hsieh, Mindy H.
    Ng, Nicholas
    Kasibhatla, Shailaja
    Tompkins, Celin
    Li, Jie
    Steffy, Auzon
    Sun, Fangxian
    Li, Chun
    Seidel, H. Martin
    Harris, Jennifer L.
    Pan, Shifeng
    [J]. ACS MEDICINAL CHEMISTRY LETTERS, 2016, 7 (07): : 676 - 680
  • [5] Discovery of Potent, Orally Bioavailable Inhibitors of Human Cytomegalovirus
    Fader, Lee
    Brault, Martine
    Desjardins, Jessica
    Dansereau, Nathalie
    Lamorte, Louie
    Tremblay, Sonia
    Bilodeau, Francois
    Bordeleau, Josee
    Duplessis, Martin
    Gorys, Vida
    Gillard, James
    Gleason, James L.
    James, Clint
    Joly, Marc-Andre
    Kuhn, Cyrille
    Llinas-Brunet, Montse
    Luo, Laibin
    Morency, Louis
    Morin, Sebastien
    Parisien, Mathieu
    Poirier, Maude
    Thibeault, Carl
    Thao Trinh
    Sturino, Claudio
    Srivastava, Sanjay
    Yoakim, Christiane
    Franti, Michael
    [J]. ACS MEDICINAL CHEMISTRY LETTERS, 2016, 7 (05): : 525 - 530
  • [6] Discovery of potent and orally bioavailable macrocyclic FXIa inhibitors
    Yang, Wu
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 254
  • [7] Discovery of Novel Pyrazolopyrimidines as Potent, Selective, and Orally Bioavailable Inhibitors of ALK2
    Nguyen, Minh H.
    Atasoylu, Onur
    Wu, Liangxing
    Kapilashrami, Kanishk
    Pusey, Michelle
    Gallagher, Karen
    Lai, Cheng-Tsung
    Zhao, Peng
    Barbosa, Joseph
    Liu, Kai
    He, Chunhong
    Zhang, Colin
    Styduhar, Evan D.
    Witten, Michael R.
    Chen, Yaoyu
    Lin, Luping
    Yang, Yan-ou
    Covington, Maryanne
    Diamond, Sharon
    Yeleswaram, Swamy
    Yao, Wenqing
    [J]. ACS MEDICINAL CHEMISTRY LETTERS, 2022, : 1159 - 1164
  • [8] Discovery of potent, selective, orally bioavailable Stearoyl-CoA desaturase 1 inhibitors
    Liu, Gang
    Lynch, John K.
    Freeman, Jennifer
    Liu, Bo
    Xin, Zhili
    Zhao, Hongyu
    Serby, Michael D.
    Kym, Philip R.
    Suhar, Tom S.
    Smith, Harriet T.
    Cao, Ning
    Yang, Ruojing
    Janis, Rich S.
    Krauser, Joel A.
    Cepa, Steven P.
    Beno, David W. A.
    Sham, Hing L.
    Collins, Christine A.
    Surowy, Teresa K.
    Camp, Heidi S.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (13) : 3086 - 3100
  • [9] Discovery of potent, selective and orally bioavailable phenylailanine based dipeptidyl peptioase IV inhibitors
    Xu, JY
    Wei, L
    Mathvink, R
    He, JF
    Park, YJ
    He, HB
    Leiting, B
    Lyons, KA
    Marsilio, F
    Patel, RA
    Wu, JK
    Thornberry, NA
    Weber, AE
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 229 : U145 - U145
  • [10] Discovery and optimization of orally bioavailable, selective and potent ATP-independent Akt inhibitors
    Chan, Thomas C. K.
    Ashwell, Mark A.
    Lapierre, Jean-Marc
    Brassard, Christopher
    Bull, Cathy
    Cornell-Kennon, Susan
    Eathiraj, Sudharshan
    France, Dennis S.
    Hill, Jason
    Koerner, Steffi
    Kelleher, Eoin
    Kizer, Darin
    Liu, Yanbin
    Link, Jeff
    Makhija, Sapna
    Moussa, Magdi
    Namdev, Nivedita
    Nicewonger, Robert
    Uppalapati, Uma
    Palma, Rocio
    Szwaya, Jeff
    Tandon, Manish
    Vensel, David
    Volak, Laurie
    Volckova, Erika
    Westland, Neil
    Wu, Hui
    Yang, Rui-Yang
    [J]. CANCER RESEARCH, 2012, 72